With recent advances in Healthcare, Personalized medicine has become a buzzword. The customization of health care, based on DNA sequencing, patient's environmental information, can lead to more efficient treatments. By integrating various sources of data, personalized medicine improves all aspects of healthcare from prevention to monitoring.

1. Prepared by Blandine Bourgoin, Innovation Analyst
For PRIME Paris Region International Mission Enterprise
June 2015
Personalized Medicine in the U.S.

2. A. Why Personalize Medicine ?
B. What is it ?
C. The Ecosystem
D. From an Economic Perspective
E. Challenges and Future Opportunities
SUMMARY

3. Imprecision Medicine
The right time
Why Personalize Medicine ?

4. Today’s Imprecision Medicine
Approved drugs in the US
Adverse effect No adverse effect
Hospitalized
Patients
7%
Troubles of adverse drugs reaction:
http://www.medscape.com/viewarticle/834273#vp_2
16%

5. Cost per Raw Megabase of DNA Sequence

6. Personalized Medicine - Example in Cancer

7. Benefits of Personalized Drugs in some Cancers
Munoz, J. & Kurzrock, R. (2012) Targeted therapy in rare cancers—adopting the orphans Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.16

8. What is Personalized Medicine ?

9. • “Tailoring of medical treatment to the
individual characteristics of each
patient”
President's Council of US Advisors
• “Choosing treatments that work well
with a person's genomic profile or with
certain characteristics in the person's
blood proteins or cell surface proteins“
• FDA
• “Healthcare that is informed by each
person’s unique clinical, genetic, and
environmental information”
• American Medical Association
Many Definitions
• “Providing the right treatment to the
right patient at the right dose at the
right time”
European Union
• “A medical model that proposes the
customization of healthcare - with
medical decisions, practices, and/or
products being tailored to the
individual patient”
Wikipedia
• “A form of medicine that uses
information about a person’s genes,
proteins, and environment to prevent,
diagnose, and treat disease.” NIH

10. Many Areas for a Huge Subject
Personalized
Medical Devices
Oncological
Vaccination
Gene TherapyTissue EngineeringRisk Profiling
Diagnostic
Data Management
Digital Health

11. Detect
early
Diagnose
accurately
Select
treatment
Monitor /
adjust
treatment
Prevent
A New Approach in Modern Medicine

12. Integrating Multiple Data
Genetic make-up
Key biomarkers
Treatment history
Behavioural preferencesEnvironmental factors

13. Multiple Stakeholders
Policy
makers
Patients Biotechs
Pharma
Cies
Providers Payers
Physicians Patients
From patients
To patients
ITCs

14. The Ecosystem

15. DIAGNOSTIC
3 TYPES OF STARTUPS
THERAPEUTIC DATA

16. President Obama’s Precision Medicine Initiative
• Voluntary
National
Research
Cohort
• 1 million
volunteers
Creation
COHORT
• With NCI
• Building a
Cancer
Knowledge
Network
Focus
CANCER
• Input from
Experts
• Patients
groups,
bioethicists,
advocates…
PRIVACY
Modernization
• FDA thinks
of new
evaluation
of NGS
REGULATORY
Public /
Private
partnerships
PARTNERSHIP
State of the Union Address, 20 January 2015, USA — Budget : 215 M$
https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative
130 M$70 M$ 10 M$5 M$

17. Apple
Researchkit Open Source Project:
– Creation of Apps for medical
research
– Easy sharing
DELL
N°1 IT Service Provider in Healthcare:
– Data storage
– Predictive analytics solution
– Health technology academy
IT Companies – Big Players

18. Google Could Have the Tools to Integrate this Data

19. From an Economic Perspective

20. Funding

21. • Big Fund Raising:
• IPO :
EXAMPLES
56 M$
50 M$ 44 M$
52M$
IPO 2005
19.55M$
IPO 2015
10M$
Roche 2014
150M$
IPO 2015

22. • Diagnostic products and services:
Oncology alone : All:
> By 2018
• Key drivers of growth:
– Payors mandating Dx to ensure proper use of
therapeutics
– Improvements in the underlying technology
and quality of Dx testing
– Physicians’ need for the information
generated by Dx to provide optimal
treatment
– Increasingly informed and active patients
– Advances in digital and info techno
Market Size
$6
Drugs in pharma pipeline
With companion diagnostic
Without
Roche pipeline
$3

23. Challenges and Future Opportunities

24. • Scientific:
– New targets, new companion diagnostics
– Data management (standardization, access…)
• Political:
– When ?
– How, what means ?
• Economical :
– Expenses, investment, public, private…
• Social :
– Ethical considerations
– Privacy but patient tracking, access to actionable knowledge
– Changes in attitude
Challenges

25. Potential Development in Oncology

26. Future Areas of Personalized Medicine

28. Immunotherapy for cancer • Raised 51$M in their Series D round
A New Thing that Could Surpass PM

29. Sources
 http://www.personalizedmedicinecoalition.org/Userfiles/PMC-
Corporate/file/pmc_case_for_personalized_medicine.pdf
 http://www.paristechreview.com/2011/11/08/revolution-personalized-medicine/
 http://en.wikipedia.org/wiki/Personalized_medicine
 http://2015sv.pmwcintl.com/program19115.pdf
 Paving the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product
Development.http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421
.pdf
 Personalized medicine: Time for one-person trials, Nicholas J. Schork, 29 April 2015

30. About PRIME & French Tech Hub
PRIME is a transatlantic innovation platform
promoting the Paris region as a center of
innovation and engaging in activities to
encourage and incentivize American companies
and organizations to invest in the Paris region.
PRIME is a subsidiary of the Paris Region
Economic Development Agency.
French Tech Hub serves as the U.S. Hub for
entrepreneurial and innovative French
companies. We provide custom-tailored services
to help our clients strategize, launch, expand, and
achieve their business potential.
For more info,
contact Marie-Perrine Durot
marie-perrine.durot@parisregionentreprises.org
For more info,
contact Marie Buhot-Launay
marie.buhotlaunay@frenchtechhub.com